Ranga Sarangarajan

Dr. Sarangarajan is a seasoned executive with extensive expertise in both scientific research and business strategy. He has consistently created value by developing novel, proprietary pipelines of assets and products within the pharmaceutical, biotechnology, and services industries. As a pioneer and early adopter, he has developed processes for successful integrated biology, technology, and computational analytics to drive data-driven biological insights and asset creation.

He has overseen the successful translation of numerous programs across multiple scientific disciplines, from early discovery through early-stage clinical development. Dr. Sarangarajan’s has extensive experience and training in the translation of basic science to clinical applications with potential for commercial development.  This unique blend of scientific and business acumen enables him to provide strategies for prioritization of resource allocation and investments in the asset/product development process.

Dr. Sarangarajan’s career has been rooted in developing research-based asset packages that solve real-world problems with unmet needs and business challenges.  His expertise spans across pharmaceutic/biotechnology, diagnostics, health and wellness industries.  He brings a unique blend of scientific expertise and strategic acumen, having pitched to venture capital, private equity and other investors with success in both dilutive and non-dilutive funding.

Experience & Expertise Highlights

§  Innovation & Strategic Growth

o  Recruit, lead and manage multidisciplinary scientific R&D teams consisting of 5-6 group leaders inclusive of 75+ employees

o   Led the development of processes enabling integration of biology discovery model & functional assay development, mass-spectrometry based high throughput multi-omic data generation

o   Led design, build, test, learn cycle of biological models for optimization of Bayesian machine learning suite for reproducibility of process achieving >75% success rate in translation of insilico outputs to in-vitro laboratory-based biology validation

o   Generated biomarkers, target discovery & validation pipelines in cardiovascular metabolic diseases (diabetes, cardiology, obesity, musculoskeletal dysfunctions [sarcopenia, bulimia, cancer cachexia]), oncology (solid tumors, pancreatic cancer, glioblastoma, breast cancer), neurology (Parkinson’s Disease, Alzheimer’s Disease), rare disease (epidermolysis bullosa, Huntington’s Disease) and immunology/inflammation;

o   Led (responsible & management) internal & external contract teams in the drug discovery & development including small and large molecule programs through preclinical validation and the development of IND packages

§  Executive Leadership

o   Create and lead scientific strategy, guiding innovation to align with business goals, steering programs focused on company long-terms goals, active risk management and ensuring overall organizational success

o   Clear scientific vision with focus on business goals, ensuring projects are aligned with company objectives

o   Active alignment of programs balancing market trends and stakeholder management in development of business packages for financing leading to success in securing financing

o     Develop scientific packages for business facing applications, successfully engaging with private equity, venture capital and other sources to secure non-dilutive and dilutive captial

o   Consistently meet or exceed corporate goals by driving efficient & effective operations of R&D and clinical translational programs

o   Led and managed Scientific Advisory Board and communication of scientific/clinical advancements & achievements to the executive leadership, Board of Directors and investors

o   Active collaboration with company leadership in providing effective governance and ensure strategic plan alignment with all key stakeholders including teams and employees

§  R&D, Clinical Translation & Operations

o   Built and managed multiple biology & cell biology operations including establishing facility for antibody production supporting validation of novel biology discovery & clinical biomarker immunoassay development & validation

o   Responsible for multi-omic biomarker driven clinical development of oncology & rare disease small molecule clinical programs including formulation, clinical supply chain management, regulatory and quality systems

o   Operational engagements with clinical CROs from site visit onboarding to clinical management with lead physician and team

o   Active leadership in the management of regulatory compliance and quality systems management

o   Successfully drove programs on timelines & allocated budgets, strategic capex investments and development of teams for effective management of infrastructure & programs

§  Strategic Partnerships

o   Established key academic, clinical and industry collaborations enhancing scientific and programmatic outcomes, increasing value of asset technology platform & asset pipeline